$21.74
6.78% yesterday
Nasdaq, Oct 15, 10:12 pm CET
ISIN
US0042251084
Symbol
ACAD

ACADIA Pharmaceuticals Inc. Stock price

$21.74
-2.93 11.88% 1M
+6.75 45.03% 6M
+3.39 18.47% YTD
+6.83 45.81% 1Y
+5.78 36.22% 3Y
-20.97 49.10% 5Y
-12.61 36.71% 10Y
+10.33 90.53% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+1.38 6.78%
ISIN
US0042251084
Symbol
ACAD
Industry

Key metrics

Basic
Market capitalization
$3.7b
Enterprise Value
$2.9b
Net debt
positive
Cash
$762.0m
Shares outstanding
168.6m
Valuation (TTM | estimate)
P/E
16.3 | 37.9
P/S
3.6 | 3.4
EV/Sales
2.9 | 2.7
EV/FCF
32.9
P/B
4.5
Financial Health
Equity Ratio
61.7%
Return on Equity
30.9%
ROCE
26.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$1.0b | $1.1b
EBITDA
$250.5m | $99.7m
EBIT
$236.8m | $97.8m
Net Income
$222.2m | $96.6m
Free Cash Flow
$88.3m
Growth (TTM | estimate)
Revenue
14.4% | 14.0%
EBITDA
645.3% | -0.4%
EBIT
969.4% | 16.0%
Net Income
626.0% | -57.3%
Free Cash Flow
9.9%
Margin (TTM | estimate)
Gross
92.0%
EBITDA
24.6% | 9.1%
EBIT
23.2%
Net
21.8% | 8.9%
Free Cash Flow
8.7%
More
EPS
$1.3
FCF per Share
$0.5
Short interest
8.8%
Employees
654
Rev per Employee
$1.5m
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

18x Buy
69%
7x Hold
27%
1x Sell
4%

Analyst Opinions

26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
69%
Hold
27%
Sell
4%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
1,019 1,019
14% 14%
100%
- Direct Costs 82 82
11% 11%
8%
937 937
15% 15%
92%
- Selling and Administrative Expenses 523 523
20% 20%
51%
- Research and Development Expense 324 324
10% 10%
32%
250 250
645% 645%
25%
- Depreciation and Amortization 14 14
19% 19%
1%
EBIT (Operating Income) EBIT 237 237
969% 969%
23%
Net Profit 222 222
626% 626%
22%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
about 10 hours ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on November 5, 2025, at 4:30 p.m. Eastern Time. The conference call will be available on Acadia's websit...
Positive
Seeking Alpha
10 days ago
ACAD's thesis centers on Nuplazid and Daybue. These are two approved and cash-generating drugs that should help ACAD fund its CNS pipeline. ACAD's Q2 2025 revenues remain solid with Nuplazid and Daybue. Also, a near-term catalyst could be the EMA's decision for Daybue by Q1 2026. They also recently secured patent wins that should protect Nuplazid until 2030 and 2038, supporting durable cash flows.
Neutral
Business Wire
14 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced one late-breaker oral platform presentation and two poster presentations to be presented at the International Congress of Parkinson's Disease and Movement Disorders® being held October 5-9, 2025, in Honolulu, Hawaii. The presentations highlight updates from the company's robust pipeline including preclinical ...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 654
Founded 1993
Website acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today